These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7752186)

  • 1. A novel approach to dual-acting thromboxane receptor antagonist/synthase inhibitors based on the link of 1,3-dioxane-thromboxane receptor antagonists and -thromboxane synthase inhibitors.
    Ackerley N; Brewster AG; Brown GR; Clarke DS; Foubister AJ; Griffin SJ; Hudson JA; Smithers MJ; Whittamore PR
    J Med Chem; 1995 May; 38(10):1608-28. PubMed ID: 7752186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ZD1542, a potent thromboxane A2 synthase inhibitor and receptor antagonist in vitro.
    Brownlie RP; Brownrigg NJ; Butcher HM; Garcia R; Jessup R; Lee VJ; Tunstall S; Wayne MG
    Br J Pharmacol; 1993 Dec; 110(4):1600-6. PubMed ID: 8306107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual-acting thromboxane receptor antagonist/synthase inhibitors: synthesis and biological properties of [2-substituted-4-(3-pyridyl)-1,3-dioxan-5-yl] alkenoic acids.
    Faull AW; Brewster AG; Brown GR; Smithers MJ; Jackson R
    J Med Chem; 1995 Feb; 38(4):686-94. PubMed ID: 7861416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ZD9583, an orally effective thromboxane A2 synthase inhibitor and receptor antagonist with a sustained duration of action in rat and dog.
    Brownlie RP; Brownrigg NJ; Butcher HM; Garcia R; Jessup R; Lee VJ; Tunstall S; Wayne MG
    J Pharm Pharmacol; 1997 Feb; 49(2):187-94. PubMed ID: 9055193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 3. Pyridinylalkyl-substituted 8-[(arylsulfonyl)amino]octanoic acids.
    Main AJ; Bhagwat SS; Boswell C; Goldstein R; Gude C; Cohen DS; Furness P; Lee W; Louzan M
    J Med Chem; 1992 Nov; 35(23):4366-72. PubMed ID: 1447737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agents combining thromboxane receptor antagonism with thromboxane synthase inhibition: [[[2-(1H-imidazol-1-yl)ethylidene]amino]oxy]alkanoic acids.
    Cozzi P; Giordani A; Menichincheri M; Pillan A; Pinciroli V; Rossi A; Tonani R; Volpi D; Tamburin M; Ferrario R
    J Med Chem; 1994 Oct; 37(21):3588-604. PubMed ID: 7932586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
    Yu SM; Wu TS; Teng CM
    Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thromboxane modulating agents. 3. 1H-imidazol-1-ylalkyl- and 3-pyridinylalkyl-substituted 3-[2-[(arylsulfonyl)amino]ethyl]benzenepropanoic acid derivatives as dual thromboxane synthase inhibitor/thromboxane receptor antagonists.
    Dickinson RP; Dack KN; Long CJ; Steele J
    J Med Chem; 1997 Oct; 40(21):3442-52. PubMed ID: 9341919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 4. 8-[[(4-Chlorophenyl)sulfonyl]amino]-4-(3-(3-pyridinyl) propyl)octanoic acid and analogs.
    Bhagwat SS; Gude C; Boswell C; Contardo N; Cohen DS; Dotson R; Mathis J; Lee W; Furness P; Zoganas H
    J Med Chem; 1992 Nov; 35(23):4373-83. PubMed ID: 1447738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approach to dual-acting platelet activating factor (PAF) receptor antagonist/thromboxane synthase inhibitor (TxSI) based on the link of PAF antagonists and TxSIs.
    Fujita M; Seki T; Inada H; Shimizu K; Takahama A; Sano T
    Bioorg Med Chem Lett; 2002 Feb; 12(3):341-4. PubMed ID: 11814792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dibenzoxepin derivatives: thromboxane A2 synthase inhibition and thromboxane A2 receptor antagonism combined in one molecule.
    Ohshima E; Sato H; Obase H; Miki I; Ishii A; Kawakage M; Shirakura S; Karasawa A; Kubo K
    J Med Chem; 1993 May; 36(11):1613-8. PubMed ID: 8496929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel agents combining platelet activating factor (PAF) receptor antagonist with thromboxane synthase inhibitor (TxSI).
    Fujita M; Seki T; Inada H; Shimizu K; Takahama A; Sano T
    Bioorg Med Chem Lett; 2002 Mar; 12(5):771-4. PubMed ID: 11858999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological activity of 4-methyl-3,5-dioxane derivatives as thromboxane A2 receptor antagonists.
    Marusawa H; Setoi H; Kuroda A; Sawada A; Seki J; Motoyama Y; Tanaka H
    Bioorg Med Chem; 1999 Nov; 7(11):2635-45. PubMed ID: 10632075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
    Watts IS; Wharton KA; White BP; Lumley P
    Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficial effects of combined thromboxane synthase inhibition/receptor blockade with CGS 22652 in a canine model of coronary thrombosis.
    Olson RW; Dotson R; Mathis J; Cohen DS; Webb RL
    Eur J Pharmacol; 1993 May; 236(1):75-87. PubMed ID: 8319746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 6,6-Disubstituted Hex-5-enoic acid derivatives as combined thromboxane A2 receptor antagonists and synthetase inhibitors.
    Soyka R; Heckel A; Nickl J; Eisert W; Müller TH; Weisenberger H
    J Med Chem; 1994 Jan; 37(1):26-39. PubMed ID: 8289199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiplatelet effect of a new inhibitor of thromboxane synthase and thromboxane A2 receptors.
    Tubaro E; Belogi L; Mezzadri CM
    Arzneimittelforschung; 1996 Jan; 46(1):35-41. PubMed ID: 8821515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors.
    Soyka R; Guth BD; Weisenberger HM; Luger P; Müller TH
    J Med Chem; 1999 Apr; 42(7):1235-49. PubMed ID: 10197967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-tert-butyl-N'-(2-cyclohexylamino-5-nitrobenzenesulfonyl)urea, BM531, a dual-acting agent for thromboxane receptor antagonism and thromboxane synthase inhibition.
    Michaux C; Dogné JM; Norberg B; Durant F; Masereel B
    Acta Crystallogr C; 2002 Oct; 58(Pt 10):o621-3. PubMed ID: 12359948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
    Vezza R; Nenci GG; Gresele P
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.